Suven Life Sciences Ltd.

111.10 -4.60 ▼-4.0%

15 April 2024, 09:07:20 AM
Volume: 2,845

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.suven.com
Market Cap 2,496.07 Cr.
Enterprise Value(EV) 2,372.10 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -4.87 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-12
Industry PE 41.38 Trailing Twelve Months Ending 2023-12
Book Value / Share 13.60 Trailing Twelve Months Ending 2023-12
Price to Book Value 8.41 Calculated using Price: 114.46
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 21.81 Cr. 218,073,717 Shares
FaceValue 1
About Suven Life Sciences Ltd.
Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.

Suven Life Sciences Ltd. Delivery

Delivered Qty
Traded Qty

Suven Life Sciences Ltd. Performance

1 Day
-3.98%
1 Week
-0.98%
1 Month
+7.81%
3 Month
-11.26%
6 Month
+54.84%
1 Year
+90.73%
2 Year
+27.34%
5 Year
-55.24%
10 Year
+55.41%

Suven Life Sciences Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 32.91 12.5 13.81 17.25 -4.75 -49.27 -67.29 -145.9 -50.17
Return on Capital Employed (%) 37.93 15.43 18.19 26.01 0.4 -54.67 -60.09 -117.81 -49.89
Return on Assets (%) 22.38 8.87 9.97 12.84 -3.31 -27.07 -28.99 -57.51 -34.54

Suven Life Sciences Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 559 595 667 767 239 143 108 96 375 338
Non Curr. Liab. 86 41 28 30 25 12 5 4 2 2
Curr. Liab. 127 211 208 226 157 120 110 102 105 10
Minority Int.
Equity & Liab. 773 846 903 1,023 421 275 222 202 483 350
Non Curr. Assets 291 319 322 350 22 116 26 41 137 134
Curr. Assets 477 528 581 674 398 160 197 160 345 216
Misc. Exp. not W/O 5
Total Assets 773 846 903 1,023 421 275 222 202 483 350

Suven Life Sciences Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 521 500 544 625 286 14 13 12 14 12
Other Income 9 20 21 23 27 14 8 2 8 22
Total Income 529 519 565 649 313 28 21 13 22 34
Total Expenditure -361 -398 -414 -424 -297 -130 -93 -134 -139 -141
PBIDT 168 121 150 225 16 -102 -72 -121 -117 -107
Interest -5 -6 -6 -5 -2 -1 -1 -1 -1 0
Depreciation -12 -18 -21 -25 -14 -4 -4 -4 -7 -7
Taxation -43 -26 -36 -72 -24 12 5
Exceptional Items 4 6 7
PAT 109 72 87 124 -24 -94 -72 -122 -118 -106
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 109 72 87 124 -24 -94 -72 -122 -118 -106
Adjusted EPS 8 5 6 9 -2 -7 -5 -8 -5 -5

Suven Life Sciences Ltd. Cash Flow

Particulars 9 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 143 68 109 70 -53 -135 -96 -128 -103
Cash Fr. Inv. -110 -39 -311 -1 37 146 56 -22 -261
Cash Fr. Finan. 179 -68 -30 -52 5 3 35 146 396
Net Change 212 -39 -232 17 -11 14 -5 -4 32
Cash & Cash Eqvt 279 241 9 26 0 15 9 5 37

Suven Life Sciences Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 60.00 64.98 64.98 64.98 69.57 69.57 69.57 69.57 69.57
Public 40.00 35.02 35.02 35.02 30.43 30.43 30.43 30.43 30.43
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Suven Life Sciences Ltd. Announcements

Fri, 12 Apr 2024
Disclosure under SEBI Takeover Regulations
Venkateswarlu Jasti has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Fri, 05 Apr 2024
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Suven Life Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Wed, 27 Mar 2024
Trading Window-XBRL
SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Closure of Trading Window

Suven Life Sciences Ltd. Technical Scans

Fri, 12 Apr 2024
Close Within 52 Week High Zone Close Within 52 Week High Zone
Making Lower Lows for 2 Days Making Lower Lows for 2 Days
High Increase in 1 Month High Increase in 1 Month
High Increase in 6 Months High Increase in 6 Months
High Increase in 1 Year High Increase in 1 Year

Suven Life Sciences Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 369,413.61 1,517.60 -1.4%
Cipla Ltd. 112,740.74 1,389.95 -0.5%
Dr. Reddy's Laboratories Ltd. 101,499.74 6,073.20 -0.2%
Divi's Laboratories Ltd. 100,325.89 3,770.00 -0.3%
Zydus Lifesciences Ltd. 96,734.30 950.00 -1.3%
Mankind Pharma Ltd. 92,896.46 2,256.00 -2.8%
Apollo Hospitals Enterprise Ltd. 92,081.85 6,325.10 -1.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.48 1,517.60 -1.4%
Cipla Ltd. Consolidated 2023-12 30.40 1,389.95 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.41 6,073.20 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-12 72.54 3,770.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-12 32.53 950.00 -1.3%
Mankind Pharma Ltd. Consolidated 2023-12 53.79 2,256.00 -2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 116.66 6,325.10 -1.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.92 1,517.60 -1.4%
Cipla Ltd. Consolidated 2023-12 4.35 1,389.95 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.78 6,073.20 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-12 7.70 3,770.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.13 950.00 -1.3%
Mankind Pharma Ltd. Consolidated 2023-12 10.46 2,256.00 -2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.63 6,325.10 -1.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,517.60 -1.4%
Cipla Ltd. Consolidated 2023-03 0.02 1,389.95 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,073.20 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,770.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 950.00 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,256.00 -2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,325.10 -1.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,517.60 -1.4%
Cipla Ltd. Consolidated 2023-03 12.85 1,389.95 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,073.20 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,770.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 950.00 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,256.00 -2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,325.10 -1.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,517.60 -1.4%
Cipla Ltd. Consolidated 2023-03 12.85 1,389.95 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,073.20 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,770.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 950.00 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,256.00 -2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,325.10 -1.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,517.60 -1.4%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,389.95 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,073.20 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,770.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 950.00 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,256.00 -2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,325.10 -1.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,517.60 -1.4%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,389.95 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,073.20 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,770.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 950.00 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,256.00 -2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,325.10 -1.3%

Suven Life Sciences Ltd. FAQ's

What is Suven Life Sciences share price?

Can I buy Suven Life Sciences shares now?

What is the Market Cap of Suven Life Sciences?

What are the key metrics to analyse Suven Life Sciences?

What is the 52 Week High and Low of Suven Life Sciences?

What is the trend of Suven Life Sciences share price?